CoChat

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Open access
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J. · 2023 · Breast Cancer Research

The DOI matches its Crossref record; 27 of the 32 references it cites were found in a registry or an index; 11 of the 15 sources its claims cite were checked for support.

Abstract

BACKGROUND: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in the final protocol-specified and exploratory (longer follow-up) OS analyses. At the time of these analyses, the full OS benefit of 1L ribociclib was not completely characterized because the median OS (mOS) was not reached. As CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) is now a preferred option for 1L HR+/HER2- ABC, we report an exploratory analysis (median follow-up, 70.8 months; 14.5 months longer than the prior analysis) to fully elucidate the OS benefit in the MONALEESA-3 1L population. METHODS: Postmenopausal patients with HR+/HER2- ABC were randomized 2:1 to 1L/2L fulvestrant + ribociclib or placebo. OS in 1L patients (de novo disease or relapse > 12 months from completion of [neo]adjuvant ET) was assessed by Cox proportional hazards model and Kaplan-Meier methods. Progression-free survival 2 (PFS2) and chemotherapy-free survival (CFS) were analyzed. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615). RESULTS: At data cutoff (January 12, 2022; median follow-up time, 70.8 months), mOS was 67.6 versus 51.8 months with 1L ribociclib versus placebo (hazard ratio (HR) 0.67; 95% CI 0.50-0.90); 16.5% and 8.6% of ribociclib and placebo patients, respectively, were still receiving treatment. PFS2 (HR 0.64) and CFS (HR 0.62) favored ribociclib versus placebo. Among those who discontinued treatment, 16.7% and 35.0% on ribociclib or placebo, respectively, received a subsequent CDK4/6i. No new safety signals were observed. CONCLUSIONS: This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS benefit of ribociclib was maintained through extended follow-up, further supporting its use in HR+/HER2- ABC.

Overview

CoChat Summary

## TL;DR

In the MONALEESA-3 exploratory follow-up analysis (median 70.8 months), first-line ribociclib plus fulvestrant prolonged overall survival versus fulvestrant alone in postmenopausal women with HR+/HER2− advanced breast cancer. The benefit was maintained despite substantial subsequent CDK4/6 inhibitor use after discontinuation.

## Key findings

  • In the first-line subgroup (de novo or late relapse), median overall survival was 67.6 months with ribociclib plus fulvestrant versus 51.8 months with placebo plus fulvestrant (HR 0.67; 95% CI 0.50–0.90).
  • The 5-year survival rate in the first-line population was 56.5% with ribociclib versus 42.1% with placebo.
  • In the first-line subgroup, PFS2 was 50.7 months with ribociclib versus 34.6 months with placebo (HR 0.64; 95% CI 0.49–0.84), and CFS was 49.2 vs 29.0 months (HR 0.62; 95% CI 0.48–0.81).
  • Among first-line patients who discontinued study treatment, 16.7% on ribociclib and 35.0% on placebo received a subsequent CDK4/6 inhibitor; after adjustment for this crossover/subsequent CDK4/6i use, the placebo-arm mOS was estimated at 50.4 months (HR 0.62; 95% CI 0.43–0.88).

## Methods

  • Phase III MONALEESA-3 randomized postmenopausal patients with HR+/HER2− advanced breast cancer 2:1 to ribociclib plus fulvestrant or placebo plus fulvestrant; treatment was blinded and stratified by liver/lung metastases and prior endocrine therapy.
  • This report is an exploratory extended follow-up analysis with data cutoff January 12, 2022 and median follow-up 70.8 months; the first-line subgroup included de novo disease or relapse >12 months after (neo)adjuvant endocrine therapy.
  • Overall survival was analyzed with Kaplan–Meier and Cox proportional hazards models; first-line CFS, TTC, and PFS2 were also assessed, and a rank-preserving structural-failure time model was used as a sensitivity analysis for placebo crossover/subsequent CDK4/6i use.

## Limitations

  • The paper states this was an exploratory analysis, so the extended follow-up results are not described as the protocol-specified final analysis.
  • The text notes cross-trial comparisons should be interpreted with caution (stated in the discussion).
  • Evident from the text: crossover/subsequent CDK4/6 inhibitor use after discontinuation complicates interpretation of the observed treatment effect, although the authors performed a sensitivity analysis to address it.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13058-023-01701-9

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 A Overall survival in patients who received ribociclib plus fulvestrant as first-line therapy. B Overall survival in ITT population. C Overall survival in patients who received ribociclib plus fulvestrant as second-line therapy
Fig. 1 A Overall survival in patients who received ribociclib plus fulvestrant as first-line therapy. B Overall survival in ITT population. C Overall survival in patients who received ribociclib plus fulvestrant as second-line therapyCC BY · PubMed Central
Fig. 2 Chemotherapy-free survival in patients who received ribociclib plus fulvestrant as first-line therapy
Fig. 2 Chemotherapy-free survival in patients who received ribociclib plus fulvestrant as first-line therapyCC BY · PubMed Central
Fig. 3 Progression free survival 2 in patients who received ribociclib plus fulvestrant as first-line therapy
Fig. 3 Progression free survival 2 in patients who received ribociclib plus fulvestrant as first-line therapyCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 2 Not checked · 25 Own results and interpretations

10 more claims

Create a free account to see all 36 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Citations

Cites

Show all 27 references

Cited by

See all 83

Metadata

Authors
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., & Slamon, D. J.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • BC Cancer Agency (CA)
  • Seoul National University (KR)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Universidad Complutense de Madrid (ES)
  • The Netherlands Cancer Institute (NL)
  • Highlands Oncology Group (US)
  • Novartis (Switzerland) (CH)
  • University of California, Los Angeles (US)
Corresponding author
Neven, P.
Venue
Breast Cancer Research
Published
2023-08-31
Volume
25
Issue
1
Pages
103-103
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W4386329445
Cited by
83
References
32
Citations by year
2026: 28 · 2025: 32 · 2024: 19 · 2023: 4
FWCI
15.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Breast Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
Novartis Pharmaceuticals Corporation
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
ribociclib, fulvestrant, HR+/HER2- advanced breast cancer, postmenopausal women, first-line therapy, CDK4/6 inhibitors, endocrine therapy, overall survival, progression-free survival, long-term follow-up, treatment discontinuation, treatment-related adverse events, drug safety and tolerability
MeSH terms
Fulvestrant, Aminopyridines, Breast Neoplasms, Female, Humans, Purines, Proportional Hazards Models, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. https://app.cochat.ai/papers/10.1186/s13058-023-01701-9
The paper
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., & Slamon, D. J. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research. https://doi.org/10.1186/s13058-023-01701-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.